Skip to main content

Table 4 Orthotopic and heterotopic models using established cell lines (ECLM)

From: Meningioma animal models: a systematic review and meta-analysis

Cell line/WHO-gr

ToA mice

Age (w)

NoC/IV

DoI (d)

TTR %(pooled animals)

IVoG

NIVoG

PuCL

Orthotopic models

 IOMM-Lee/malignant

Athymic nu/nu [24, 49, 54, 66, 70, 74, 77, 80], SCID [44, 55], Nude [45, 68, 74, 78, 82, 83], Swiss nude [47, 53, 59, 61, 62, 79, 81], BALB/c [50, 58, 84], NOD(shi-SCID,IL-2Rgamma(null,c)(NOG) [60], CD1 [67], NCr-Foxn1 (nu) [85]

3 [67], 4–10 [24, 44, 45, 49, 50, 54, 55, 58,59,60,61, 66, 74, 77,78,79, 81,82,83,84,85], > 9 [47], 12–15 [62], 10–22 [53],

ND [68, 70, 75, 80]

(104) [49], (5 × 104) [60, 66, 83], (105) [50, 62, 67, 78, 82], (1.5 × 105) [58], (2 × 105) [85] (2.5 × 105) [47, 53, 54, 59, 61, 79, 83, 84], (4 × 105) [45], (5 × 105) [66,67,68, 70, 75], (106) [24, 44, 74, 77, 81], (3 × 106) [66]/(0.5) [66, 83], (1) [66], (2) [62, 84]

(2.5) [47, 53, 79, 83], (3) [50, 58, 60, 66, 67, 77], (5) [54, 59, 61, 66, 81], (3–10) [44], (10) [24, 68, 74, 78, 82]

CN-ND [55, 80], IV-ND [45, 49, 55, 68, 70, 75, 80, 85]

CD (4–12) [24], (5) [60], (9) [61], (10) [59, 60], (11) [53], (14) [58, 60, 62, 67, 74, 81], (21) [78], (28) [75]

SS (10) [60, 66], (11) [85], (12) [66], (13) [77], (15) [53], (17) [47, 66], (20) [66, 79], (21) [49, 84], (23) [50], (27) [45], 15–21 [83]

ND [44, 54, 55, 68, 70, 80, 82]

100% (504/504) [24, 45, 50, 53, 58,59,60,61,62, 66,67,68, 70, 75, 77,78,79, 81, 82, 84]

ND [44, 47, 49, 54, 55, 74, 80, 83, 85]

Histology [24, 44, 45, 47, 50, 53, 54, 60,61,62, 66,67,68, 70, 74, 75, 77,78,79, 81, 82, 84, 85]

IHC [24, 44, 45, 53, 58,59,60, 66, 68, 70, 77, 78, 80, 84]

BLI [45, 49, 50, 66, 67, 85]

MRI [44, 47, 53, 55, 59, 61, 62, 67, 79, 81, 83]

FI [58, 60]

29 [24, 44, 45, 47, 49, 50, 53, 54, 58,59,60,61,62, 66,67,68, 70, 74, 75, 77,78,79,80,81,82,83,84,85]

a[55]

 BEN-MEN-1/benign

NSG [89, 92], SCID [55, 90, 91], CD1 [21]

6–12 [21, 55, 89,90,91,92]

(0.5–1.0 × 106) [91], (106) [21, 89, 90]/3–5 [21, 89,90,91,92]

CN-ND [55]

CD (35 [90], 98 [89, 92], 107 [21], 180 [91])

ND [55]

100% (45/45) [21, 92]

ND [55, 89,90,91]

Histology [21, 55, 90,91,92]

IHC [21, 90,91,92]

BLI [89,90,91,92]

MRI [55, 91]

6 [21, 55, 89,90,91,92]

 CH-157/malignant

NCr-Foxn1(nu) [85], NSG [93], CD1 [67, 94], nude [43, 98]

3 [67, 94]

4–6 [43, 85, 93, 98]

(104) [67], (105) [43, 67, 94], (2 × 104) [93], (2 × 105) [85], (5 × 105) [67], (106) [67]

(5 × 104–5 × 105) [98], (105–106) [98]

/(3–8) [67, 93, 94, 98], IV-ND [43, 85]

CD 14 [43], 15 [93], 20 [94], 30 [98]

SS 12–15 [85], 16–24 [67]

100% (66/66) [93, 94] 91% (20/22) [98]

90% (45/50) [67]

79% (15/19) [98] ND [43, 85]

Histology [43, 67, 85, 93, 94, 98]

IHC [43, 67, 94]

BLI [43, 67, 85, 93, 94]

MRI [98]

6 [43, 67, 85, 93, 94, 98]

 KT21MG1/malignant

Swiss nude [59, 61], NMRI nu/nu [99], athymic [101], SCID [90]

5–6 [99, 101]

8–10 [59, 61, 90]

5 × 104 [101]; 2.5 × 105 [59, 61]; 5 × 105 [90]; 106 [99]

/0.5 [101], 5 [59, 61, 90]; IV-ND [99]

CD 10 [99], 17 [61], 21 [59], 42 [90]

SS 19 [101]

100% (50/50) [59, 61, 99]

ND [90, 101]

Histology [90, 99]

IHC [59, 90, 99, 101]

BLI [90]

MRI [59, 61]

5 [59, 61, 90, 99, 101]

 F5

NOD/SCID [107], Swiss nude [81], BALC/-nu/nu [106]

6–8 [81, 107]

(2.5 × 105) [107], (106) [81], WT [106]/(5) [81], IV-ND [107]

CD 14 [107], 29 [81]

SS (29) [106]

100% (15/15) [81], 94% (15/16) [106], ND [107]

Histology [81, 106, 107]

IHC [106, 107]

MRI [81, 107]

3 [81, 106, 107]

 MN3

SCID [113, 114]

7–8 [113, 114]

(7.5 × 104) [113, 114]/(3) [113, 114]

SS 92 [114]

ND [113]

100% (25/25) [113, 114]

Histology [113, 114] IHC [113, 114]

–

2 [113, 114]

 MN8

SCID [114]

7–8 [114]

(5 × 104)(114)/(3) [114]

ND [114]

ND [114]

Histology [114] IHC [114]

–

1 [114]

 HKBMM

BALB/C-nu/nu [84]

6–8 [84]

(2.5 × 105) [84]/(2) [84]

SS 27 [84]

100% (24/24) [84]

Histology [84] IHC [84]

–

1 [84]

 Me10T Me3TSC

Athymic [69]

4 [69]

(106) [69]/(5) [69]

CD (112) [69]

100% (6/6) [69] Me10T

100% (6/6) [69] Me3TSC

Histology [69]

IHC [69]

–

1 [69]

Heterotopic models

 IOMM-Lee/malignant

Athymic nu/nu [49, 57, 71, 75, 76], BALB/c-nu [22, 46, 48, 51, 52, 56, 84], SCID [55, 63], Swiss nude [59, 61, 62, 83], nude [45, 64, 65, 86, 88], CD1 [20, 72, 73], C57BL/6 [87]

3 [20, 72, 73], 4–6 [46, 51, 52, 56, 71, 87, 88], 6 [45, 55], 6–8 [49, 64, 65, 76, 84, 86], 8 [22, 48, 58], 8–10 [59, 61, 83], 7–11 [62], ND [57, 63, 75]

(2 × 104) [46], (1.5 × 105) [58], (5 × 105) [20, 46, 72], (106) [57, 63, 71, 73, 76], (1.5 × 106) [20], (2 × 106) [45, 86, 88], (3 × 106) [59, 61, 62, 83], (4 × 106) [64], (5 × 106) [48, 49, 52, 65, 75, 84], (107) [22, 55, 56, 87], (5 × 107) [51]/(3) [58]

(100) [46, 48, 55, 58, 59, 61, 63, 72, 73, 75, 76, 83, 84, 86, 87], (200) [22, 51, 88], (500) [20], IV-ND [45, 49, 52, 56, 57, 62, 64, 65, 71]

CD 12 [52], 14 [58, 62, 76], 16 [84], 17 [59], 21 [57, 61, 65, 83], 25 [64, 86], 26 [71], 28 [46, 48, 75, 88], 30 [56], 31 [49], 34 [51], 35 [45], 43 [72], 45 [87], 56 [20, 73]

ND [22, 55]

100% (432/432) [22, 45, 46, 48, 51, 52, 57,58,59, 61, 62, 64, 65, 71,72,73, 76, 83, 86, 87]

95% (19/20) [20]

87% (13/15) [63]

77% (23/30) [56]

ND [49, 55, 75, 84, 88]

Histology [20, 22, 45, 49, 51, 52, 63, 65, 72, 73, 75]

IHC [20, 22, 45, 46, 48, 49, 51, 52, 58, 59, 61, 63,64,65, 71,72,73, 86,87,88]

Caliper [45, 49, 51, 52, 55,56,57,58,59, 61, 62, 64, 71, 72, 76, 83, 84, 86, 87]

FI [58]

28 [20, 22, 45, 46, 48, 49, 51, 52, 55,56,57,58,59, 61,62,63,64,65, 71,72,73, 75, 76, 83, 86, 87]

a[84, 88]

 CH-157/malignant

NU/NU [6, 95, 96], CD1 [20, 72], BALB/c-nu [97],

3 [20, 72],

5–6 [6]

ND [95,96,97]

(5 × 105) [72], (106–1.25 × 106) [20], (1.5 × 106) [95,96,97], (3 × 106) [6]

/(100–500) [20, 72, 95, 97]; IV-ND [6, 96]

CD 28 [6], 30 [95], 43 [72],

OC 43 [20]

ND [96, 97]

100% (47/47) [20, 72, 95, 96]

ND [6, 97]

Histology [20, 72, 97]

IHC [6, 20, 72, 95, 97]

Caliper [20, 72]

PET [95, 96]

FI [97]

7 [6, 20, 72, 95,96,97]

a[88]

 HKBMM

BALB/cAJcl-nu/nu [102], Nude [103], BALB/c-nu [84, 104]

4–6 [103], 6–9 [84, 102, 104]

(5 × 105) [102], (106) [102], (5 × 105) [84], 7 × 106) [103], (107) [104]/(100) [84], (200) [102, 103], IV-ND [104]

CD 16 [84], 49 [103], 56 [104], 140 [102]

ND [102]

100% (28/28) [102,103,104]

Histology [103, 104] IHC [103, 104]

Caliper [84, 102]

4 [102,103,104]

a[84]

 NCH93

NMRI/nu [110, 111, 115]

5–6 [110, 111, 115]

(106) [110], (4 × 106) [111, 115]/(100) [110, 111], (200) [115]

SS 15 [111], 21 [115], 49 [110]

100% (44/44) [110, 111, 115]

Histology [110, 111, 115] IHC [110, 111, 115]

Caliper [110, 111, 115]

3 [110, 111, 115]

 SF4433

Athymic [108, 109]

5 [108], 6 [109]

(2 × 105) [108, 109]/(100) [108, 109]

CD 14 [109], 17 [108]

100% (40/40) [108, 109]

-

BLI [108, 109]

2 [108, 109]

 SF3061

Athymic [109]

6 [109]

(2 × 106) [109]/(100) [109]

CD 11 [109]

100% (30/30) [109]

-

Caliper [109]

1 [109]

 KT21MG1/malignant

ICR nu/nu [100]

4–5 [100]

8 × 106 [100]/IV-ND [100]

CD 90 [100]

100% (3/3) [100]

Histology [100] IHC [100]

–

1 [100]

 F5

BALC/c [106]

6 [106]

WT [106]

SS 28 [106]

100% (40/40) [106]

IHC [106]

–

1 [106]

 HBL52

BALB/c [112]

7 [112]

(105) [112]/(200) [112]

CC 49 [112]

SS (27) [112]

100% (96/96) [112]

IHC [112]

Caliper [112]

1 [112]

 KCI-MENG1-LP/HP

SCID/NCr [105]

ND [105]

ND [105]

Serial transplantations [105]

ND [105]

Histology(105) IHC [105]

–

1 [105]

  1. ToA: Type of animal, NoC/IV: Number of cells/injection volume (μl), DoI: Duration of incubation, TTR: Tumor take rate, w: weeks, d: days, ND: Not described to a degree of certainty/Not described at all, PuCL: Papers using the cell line, IVoG: Validation of growth, NIVoG: Non-invasive validation of growth, BLI: Bioluminescence, SS: Survival study—number of days 50% dead (control animals) or human endpoint met, CD: Chosen day of death, OC: Other causes for termination, FI: Fluorescence imaging
  2. aUncertain use of cells in model, WT (whole tumor from original paper)
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us